Redenlab brings on Dr Amir Lahav as Chief of Digital Health and Strategy

Redenlab extend their reach in the #speech neuroscience and clinical trials by adding #leaders at the forefront of #digitalhealth & #virtualtrials. Formerly with Pfizer & Harvard University, Amir Lahav brings 15+ years of experience in the healthcare industry, academic research, clinical data science, and Around the Pill solutions.

Dr Amir Lahav is a clinical neuroscientist and a leading innovator in digital health with a special focus on developing and validating novel biomarkers and AI-driven technology for remote monitoring of patients with neurodegenerative diseases. Amir has 15+ years of experience in the healthcare industry, academic research, clinical data science, and Around the Pill solutions. He is currently the Head of R&D at Mitsubishi Tanabe Pharma Holding America, and a freelance consultant for several HealthTech companies in the DTx space. Formerly, Amir served as the Head of Digital Innovation at Pfizer’s Rare Disease Unit, where he led the development of technology solutions and mobile health apps, from proof-of-concept studies to global scale-up implementation in clinical trials. Prior to pharma, Amir was a professor of pediatrics at Harvard Medical School and a PI on multiple technology-driven clinical trials. Amir leads Redenlab’s digital health & strategy, driving innovation in new markets and disease groups.

Related Post

  • Posted on 15 July, 2022
    MEDIA RELEASEFRIDAY 15 JULY 2022 As many as 70% of people who experience stuttering have a family member who also...
    • Posted on 28 November, 2021
      Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal dementia. Adolfo...
      • Posted on 17 October, 2021
        Redenlab’s latest iOS application provides state of the art audio capture, storage and analysis of speech and language data for...